First Mercantile Trust Co. Cuts Stake in Regeneron Pharmaceuticals Inc (REGN)

First Mercantile Trust Co. lowered its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 16.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,500 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. First Mercantile Trust Co.’s holdings in Regeneron Pharmaceuticals were worth $564,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Harding Loevner LP grew its stake in Regeneron Pharmaceuticals by 589.2% in the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after purchasing an additional 3,131,966 shares during the last quarter. American Century Companies Inc. grew its stake in Regeneron Pharmaceuticals by 2.3% in the third quarter. American Century Companies Inc. now owns 917,554 shares of the biopharmaceutical company’s stock valued at $410,257,000 after purchasing an additional 20,218 shares during the last quarter. Orbimed Advisors LLC grew its stake in Regeneron Pharmaceuticals by 22.7% in the third quarter. Orbimed Advisors LLC now owns 572,770 shares of the biopharmaceutical company’s stock valued at $256,097,000 after purchasing an additional 106,000 shares during the last quarter. Legal & General Group Plc grew its stake in Regeneron Pharmaceuticals by 0.7% in the third quarter. Legal & General Group Plc now owns 371,110 shares of the biopharmaceutical company’s stock valued at $165,929,000 after purchasing an additional 2,729 shares during the last quarter. Finally, Old Mutual Global Investors UK Ltd. grew its stake in Regeneron Pharmaceuticals by 500,446.2% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock valued at $145,472,000 after purchasing an additional 325,290 shares during the last quarter. Institutional investors own 65.69% of the company’s stock.

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) opened at $336.38 on Friday. The company has a current ratio of 2.14, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals Inc has a twelve month low of $314.99 and a twelve month high of $543.55. The company has a market capitalization of $37,680.00, a PE ratio of 32.59, a P/E/G ratio of 1.22 and a beta of 1.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the Zacks’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter in the previous year, the company posted $3.04 earnings per share. The company’s revenue was up 28.9% compared to the same quarter last year. analysts expect that Regeneron Pharmaceuticals Inc will post 14.13 EPS for the current fiscal year.

Several research firms have issued reports on REGN. BTIG Research reiterated a “buy” rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 22nd. Guggenheim set a $530.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Friday. Robert W. Baird upgraded Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Friday. They noted that the move was a valuation call. Leerink Swann cut their target price on Regeneron Pharmaceuticals from $568.00 to $502.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the company an “equal weight” rating in a research note on Friday. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $463.19.

WARNING: “First Mercantile Trust Co. Cuts Stake in Regeneron Pharmaceuticals Inc (REGN)” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.com-unik.info/2018/02/10/first-mercantile-trust-co-cuts-stake-in-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit